1
Erik De Clercq, Antonin Holy, Ivan Rosenberg: Therapeutical application of phosphonylmethoxyalkyl adenines. Stichting Rega VZW, Ceskoslovenska Akademie VED, Birch Stewart Kolasch & Birch, February 9, 1988: US04724233 (53 worldwide citation)

The (S) and (RS) forms of certain phosphonylmethoxyalkyl adenines and their salts have an antiviral effect against several DNA viruses and can be used for the treatment of virus diseases in human and veterinary medicine.


2

3
Christopher McGuigan, Jan Balzarini, Erik De Clercq: Anti-viral pyrimidine nucleoside analogues. University College Cardiff Consultants, Rega Foundation, Woodcock Washburn, March 28, 2006: US07019135 (13 worldwide citation)

Compounds of the general formula (I) are described wherein R, R′, R″, Q, T, T′, T″, T″′, W, X, and Z are as defined in the specification. Compounds according to the invention preferably display potent anti-viral activity against, for example, cytomegalo virus.


4
Antonin Holy, Erik de Clercq: Antivirally active adenine derivatives. Ceskoslovenska Akademie Ved, Stichting Rega VZW, Birch Stewart Kolasch & Birch, August 12, 1986: US04605658 (11 worldwide citation)

Certain esters of 3-(adenin-9-yl)-2-hydroxypropanoic acid are disclosed which exhibit an improved broad spectrum antiviral activity while having a low toxicity for living cells. They can be used for treatment of virus diseases in human and veterinary practice.


5
Erik De Clercq, Antonin Holy: Therapeutic application of (S) -or (RS)-9-(2, 3-dihydroxypropyl) adenine for use as antiviral agents. Stichting Rega V Z W, Ceskoslovenska Akademie Ved, Brumbaugh Graves Donohue & Raymond, October 28, 1980: US04230708 (11 worldwide citation)

The specification describes the use of S or RS 9-(2, 3-dihydroxypropyl) adenine either alone or in combination with ara-A for the treatment of virus diseases.


6

7
Zeger Debyser, Petr Cherepanov, Erik De Clercq: Integrase cofactor. K U Leuven Research & Development, Clark & Elbing, April 7, 2009: US07514233 (9 worldwide citation)

The present invention provides integrase interacting proteins including cofactors which promote strand transfer activity of viral integrase, more particularly HIV integrase, and methods and uses relating thereto. The present invention also relates to methods of identifying molecules interacting with ...


8
Zeger Debyser, Petr Cherepanov, Erik De Clercq: Integrase cofactor. K U Leuven Research & Development, Clark & Elbing, August 30, 2011: US08008470 (8 worldwide citation)

The present invention provides nucleic acid molecules which include a region specifically interacting with the nucleic acid encoding the LEDGF/P75 protein or the nucleic acid encoding a fragment of a LEDGF/P75 protein and methods and uses of such nucleic acid molecules.


9
Erik de Clercq, Gabriel A Verhelst, Albert S Jones, Richard T Walker: E-5-(2-Halogenovinyl)-2-deoxycytidines. The University of Birmingham, Stichting Rega V Z W, Birch Stewart Kolasch & Birch, May 10, 1983: US04382925 (8 worldwide citation)

The invention relates to E-5-(2-halogenovinyl)-2'-deoxycytidines, e.g. E-5-(bromovinyl)-2'-deoxycytidine and E-5-(2-iodovinyl)-2'-deoxycytidine. These substances are endowed with specific antiviral activities towards herpes simplex virus and with an extremely low toxicity which makes them useful in ...


10
Masanori Baba, Dominique Schols, Rudi Pauwels, Jan Balzarini, Erik De Clercq: Antiviral agents against aids-causing virus. Toray, Austin R Miller, January 21, 1997: US05596018 (4 worldwide citation)

An antiviral agent against viruses causative of AIDS, containing fuchsinic acid as an active ingredient.